Establishment Labs Reports 31.7% Revenue Growth in Q2 2026, Net Loss Improves

Establishment Labs Holdings Inc. reported significant financial performance improvements in its latest 10-Q filing for the second quarter of 2026. The company generated revenue of $67.5 million for the three months ended June 30, 2026, marking a 31.7% increase from $51.3 million in the same period last year. For the first half of 2026, total revenue reached $127.4 million, a 37.5% increase compared to $92.7 million for the first half of 2025. Despite these gains, the company reported a net loss of $11.7 million for the second quarter, an improvement from a loss of $16.6 million in the prior year, and a total net loss of $25.1 million for the first half of 2026, down from $37.3 million in the same period of 2025.

The company’s operational metrics also reflected positive trends. Sales in the United States surged by $27.9 million for the first half of 2026, contributing significantly to the overall revenue growth. The gross margin improved to 70.7% for the six months ended June 30, 2026, compared to 68.1% in the previous year, attributed to a favorable sales mix and higher selling prices in the U.S. market. The company’s total assets decreased slightly to $351.9 million as of June 30, 2026, from $357.2 million at the end of 2025, while total liabilities also saw a reduction to $330.3 million from $333.6 million.

Strategically, Establishment Labs has made notable advancements, including the appointment of new executives to its leadership team. Taylor Harris joined the Board of Directors, and Cassandra Harris was appointed as Senior Vice President and Chief Financial Officer. The company also entered into an Amended and Restated Credit Agreement in April 2026, securing up to $300 million in term loans, which will support its operational and growth initiatives. Approximately $259 million of the proceeds from the initial borrowing were used to repay previous obligations, enhancing the company’s financial flexibility.

In terms of operational developments, Establishment Labs reported a cash balance of $71.2 million as of June 30, 2026, down from $75.6 million at the end of 2025. The company’s employee headcount remained stable, and it continues to focus on expanding its market presence, particularly in the U.S. where it began selling its Motiva Implants in October 2024. The company’s ongoing efforts to educate clinicians and enhance product offerings are expected to drive further adoption and market share growth.

Looking ahead, Establishment Labs remains optimistic about its growth trajectory, emphasizing the importance of its innovative product lines and market expansion strategies. The company anticipates that its available cash and projected cash flow from operations will be sufficient to meet liquidity requirements for at least the next 12 months. However, it acknowledges the inherent risks associated with market conditions, competition, and regulatory challenges that could impact future performance.